SCHEMBL31683652

SCHEMBL31683652

Cc1ccc(S(=O)(=O)n2ccc3c(-c4cc(C(C)(C)O)ccc4Oc4ccc(N5CCC6(CCNCC6)C5)cc4)cn(C)c(=O)c32)cc1

nearest known ligand 0.50

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 20/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31683654 0.85 BRD4 (0.49) BRD4
SCHEMBL30824846 0.82 BRD4 (0.55) BRD4
SCHEMBL30824888 0.81 BRD4 (0.52) BRD4
SCHEMBL30811967 0.80 BRD4 (0.49) BRD4
SCHEMBL31683577 0.80 BRD4 (0.48) BRD4
SCHEMBL30812157 0.79 BRD4 (0.52) BRD4
SCHEMBL30811953 0.79 BRD4 (0.49) BRD4
SCHEMBL30824787 0.78 BRD4 (0.48) BRD4
SCHEMBL30824947 0.78 BRD4 (0.57) BRD4
SCHEMBL30812104 0.78 BRD4 (0.46) BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558428-B2 Heterobifunctional compounds and their use in treating disease HALDA THERAPEUTICS OPCO, INC. (US) 2026-02-24 — — US disclosed
US-20250281623-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. 2025-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558428-B2 Heterobifunctional compounds and their use in treating disease BRCA1, H1-0, FOXM1 BRD4 623/4885
US-20250281623-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE VHL, HMBS, BRCA1 BRD4 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback